NeoLumina’s license for Filament’s botanical psilocybin drug candidate provides exclusive global right to clinical and commercial development for eating disorders VANCOUVER, BC, June 30, 2023 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced an exclusive global licensing…
